文献速递认知障碍与痴呆

脑脊液与[18F]FDG-PET生物标志物在评估非典型和早发性阿尔茨海默病痴呆病例中的不一致性与一致性

Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases.
PubMed 文献 · Neurology · 2022-10-20

本研究回顾性评估了三级记忆门诊中符合AD生物标志物检查适用标准的非典型和/或早发性痴呆患者,比较脑脊液Aβ42、P-tau181、总tau与[18F]FDG-PET视觉判读的一致性。结果显示[18F]FDG-PET与脑脊液AD生物标志物在近20%病例中不一致,[18F]FDG-PET鉴别脑脊液AD阳性与阴性的敏感度和特异度均高于80%。

要点

  • 在非典型和/或早发性痴呆患者中,[18F]FDG-PET与脑脊液AD生物标志物近20%不一致。
  • [18F]FDG-PET鉴别脑脊液AD阳性的敏感度81%、特异度81%,阳性预测值87%、阴性预测值72%。
  • 脑脊液Aβ42和P-tau181对AD特异,[18F]FDG-PET的拓扑信息可能提供补充信息。

核心结论

  • 在本文临床系列中,脑脊液与[18F]FDG-PET在近20%的病例中不一致。
  • 脑脊液Aβ42和P-tau181生物标志物对AD特异,[18F]FDG-PET的拓扑信息可能提供补充信息。

研究设计与样本

  • 回顾性评估在三级记忆门诊接受评估的非典型和/或早发性痴呆患者。
  • 所有个体均接受脑脊液Aβ42、磷酸化tau(P-tau181)和总tau评估以及脑[18F]FDG-PET检查。
  • [18F]FDG-PET数据由2名核医学专家视觉判读为符合AD或非AD,脑脊液生物标志物结果同样分组为AD生物标志物阳性/阴性。
  • 采用列联表和Kappa系数确定所有个体中脑脊液与[18F]FDG-PET结果之间的一致与不一致程度。
  • 136名个体在早发性和/或非典型痴呆评估中同时接受了[18F]FDG-PET和腰椎穿刺。

主要发现

  • [18F]FDG-PET显示提示AD的模式见于43%的患者,而脑脊液生物标志物显示符合AD的结果见于57%的参与者。
  • 在符合AD生物标志物检查标准的患者中,[18F]FDG-PET与脑脊液AD生物标志物在近20%的病例中不一致。
  • 12%的[18F]FDG-PET扫描符合AD的个体脑脊液结果AD阴性;7%的[18F]FDG-PET扫描不符合AD的个体脑脊液结果AD阳性,可能提示非典型AD变异型或程度较轻的神经退行性变。
  • [18F]FDG-PET区分脑脊液AD阳性与AD阴性患者的敏感度和特异度均高于80%(敏感度:81%,95%CI=71-88%;特异度:81%,95%CI=68-89%)。
  • [18F]FDG-PET的阳性预测值为87%(95%CI=78-93%),阴性预测值为72%(95%CI=60-82%)。

关键数值与推荐

  • 脑脊液AD生物标志物评估包括Aβ42、磷酸化tau(P-tau181)和总tau。
  • [18F]FDG-PET由2名核医学专家视觉判读为符合AD或非AD。
  • [18F]FDG-PET区分脑脊液AD阳性与AD阴性的敏感度81%(95%CI=71-88%)、特异度81%(95%CI=68-89%)。
  • [18F]FDG-PET的阳性预测值87%(95%CI=78-93%)、阴性预测值72%(95%CI=60-82%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To assess the concordance and discordance between the core Alzheimer disease (AD) CSF biomarkers and [18F]fluorodeoxyglucose (FDG)-PET patterns evaluated clinically in memory clinic patients who meet appropriate use criteria for AD biomarker investigations. METHODS: We retrospectively assessed participants with atypical and/or early-onset dementia evaluated at a tertiary care memory clinic. All individuals underwent CSF evaluations for Aβ42, phosphorylated tau (P-tau181) and total tau, and brain [18F]FDG-PET. [18F]FDG-PET data were visually interpreted by 2 nuclear medicine experts as being consistent with AD or non-AD. CSF biomarker results were similarly grouped into AD biomarker positive/negative. Contingency tables and Kappa coefficients were used to establish the level of agreement and disagreement between CSF and [18F]FDG-PET results in all individuals. RESULTS: One hundred thirty-six individuals had both [18F]FDG-PET and lumbar puncture performed as part of the early-onset and/or atypical dementia assessments. [18F]FDG-PET showed a pattern suggestive of AD in 43% of patients, while CSF biomarkers showed results consistent with AD in 57% of participants. In patients who met criteria for AD biomarker investigations, we found that [18F]FDG-PET was discordant with CSF AD biomarkers in nearly 20% of cases; 12% of individuals with [18F]FDG-PET scans consistent with AD had AD-negative CSF results; and 7% of individuals with [18F]FDG-PET scans not consistent with AD had AD-positive CSF results, potentially suggesting atypical AD variants or less advanced neurodegeneration. [18F]FDG-PET discriminated patients with an AD-positive CSF profile from patients with an AD-negative profile with a sensitivity and specificity higher than 80% (sensitivity: 81%, 95% CI = 71-88%, SP: 81%, 95% CI = 68-89%). Furthermore, [18F]FDG-PET had a positive predictive value of 87% (95% CI = 78-93%) and a negative predictive value of 72% (95% CI = 60-82%). DISCUSSION: CSF and [18F]FDG-PET disagreed in nearly 20% of the cases studied in this clinical series. While CSF Aβ42 and P-tau181 biomarkers are specific for AD, the topographical information from [18F]FDG-PET may provide complementary information.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Quispialaya KM, Therriault J, Aliaga A, et al. Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases. Neurology. 2022. PMID: 36266044. doi:10.1212/WNL.0000000000201198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。